Cost for Inpatient Care of Venous Thrombosis

Lissovoy, Gregory de; Yusen, Roger D.; Spiro, Theodore E.; Krupski, William C.; Champion, Annette Hust; Sorensen, Sonja

doi:10.1001/archinte.160.20.3160

Cited by 36 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of studies have indicated that the LMWHs are economically superior to UFH both for DVT treatment [80,83,84], and for bridging to long-term anticoagulation [85-87], and they are at least non-inferior or superior to warfarin in preventing VTE following orthopedic surgery [88,89]. However, there are limited data regarding the economics associated with thromboprophylaxis following cancer surgery.…”

Section: Introductionmentioning

confidence: 99%

The potential benefits of low-molecular-weight heparins in cancer patients

Robert

2010

J Hematol Oncol

View full text Add to dashboard Cite

Cancer patients are at increased risk of venous thromboembolism due to a range of factors directly related to their disease and its treatment. Given the high incidence of post-surgical venous thromboembolism in cancer patients and the poor outcomes associated with its development, thromboprophylaxis is warranted. A number of evidence-based guidelines delineate anticoagulation regimens for venous thromboembolism treatment, primary and secondary prophylaxis, and long-term anticoagulation in cancer patients. However, many give equal weight to several different drugs and do not make specific recommendations regarding duration of therapy. In terms of their efficacy and safety profiles, practicality of use, and cost-effectiveness the low-molecular-weight heparins are at least comparable to, and offer several advantages over, other available antithrombotics in cancer patients. In addition, data are emerging that the antithrombotics, and particularly low-molecular-weight heparins, may exert an antitumor effect which could contribute to improved survival in cancer patients when given for long-term prophylaxis. Such findings reinforce the importance of thromboprophylaxis with low-molecular-weight heparin in cancer patients.

show abstract